Evidence map›Paper›PMID 32828600›Full record

Observational studyEuropean urology2020

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.

Nicholas J Salgia, Paulo G Bergerot, Manuel Caitano Maia, Nazli Dizman, JoAnn Hsu, John D Gillece, Megan Folkerts, Lauren Reining, Jeffrey Trent, Sarah K Highlander and 1 more

3 registry-linked trialsAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 132 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 8 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04819958 unknown statusnot on this mapstarted 2021, after this paper: background citation

The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Short-term Outcome and Long-term Outcome of Patients With Gastric Cancer

TypeobservationalSponsorFujian Medical UniversityRan2021 to 2021Enrolled20ConditionsStomach Cancer
NCT05119010 naterminatednot on this mapstarted 2023, after this paper: background citation

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2023 to 2024Enrolled3ConditionsMetastatic Renal Cell CarcinomaArmsContinuous ketogenic diet, Discontinuous ketogenic diet, beta-hydroxybutyrate (BHB) supplementation
NCT07007169 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Mediterranean Diet and Inequality in Early Breast Cancer: A Multicenter Randomized Clinical Trial

TypeinterventionalSponsorEsbjerg Hospital - University Hospital of Southern DenmarkRan2025 to 2036Enrolled105ConditionsEarly Breast CancerArmsThe goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods, minimizing the amount of ultra-processed food., Standard Diet
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 8 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Frontiers in immunology · 2022
    Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Review
  20. Review

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Nicholas J SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Paulo G BergerotDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Manuel Caitano MaiaCentro de Oncologia do Paraná, Curitiba, Brazil.
Nazli DizmanDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
JoAnn HsuDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
John D GillecePathogen and Microbiome Division, Translational Genomics Research Institute North, Flagstaff, AZ, USA.
Megan FolkertsPathogen and Microbiome Division, Translational Genomics Research Institute North, Flagstaff, AZ, USA.
Lauren ReiningPathogen and Microbiome Division, Translational Genomics Research Institute North, Flagstaff, AZ, USA.
Jeffrey TrentTranslational Genomics Research Institute, Phoenix, AZ, USA.
Sarah K HighlanderPathogen and Microbiome Division, Translational Genomics Research Institute North, Flagstaff, AZ, USA. Electronic address: shighlander@tgen.org.
Sumanta K PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
City of Hope · USTranslational Genomics Research Institute · USInstituto de Oncologia do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical models and early clinical data suggest an interplay between the gut microbiome and response to immunotherapy in solid tumors including metastatic renal cell carcinoma (mRCC). We sought to characterize the stool microbiome of mRCC patients receiving a checkpoint inhibitor (CPI) and to assess treatment-related changes in microbiome composition over the course of CPI therapy. Stool was collected from 31 patients before initiation of nivolumab (77%) or nivolumab plus ipilimumab (23%) therapy, of whom 58% experienced clinical benefit. Greater microbial diversity was associated with clinical benefit from CPI therapy (p =  0.001), and multiple species were associated with clinical benefit or lack thereof. Temporal profiling of the microbiome indicated that the relative abundance of Akkermansia muciniphila increased in patients deriving clinical benefit from CPIs. This study substantiates results from previous CPI-related microbiome profiling studies in mRCC. Temporal changes in microbiome composition suggest potential utility in modulating the microbiome for more successful CPI outcomes. PATIENT SUMMARY: We compared the composition and diversity of the gut microbiome in patients receiving immunotherapy for renal cell carcinoma. We found that higher microbial diversity is associated with better treatment outcomes. Treatment response is characterized by changes in microbial species over the course of treatment.

Indexed as

Gastrointestinal MicrobiomeAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellFecesHumansImmune Checkpoint InhibitorsIpilimumabKidney NeoplasmsNivolumabProspective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsIpilimumabNivolumabBacteriomic profilingCheckpoint inhibitorMicrobiomeNivolumabRenal cell carcinoma

Identifiers

PMID32828600
OpenAlexW3068877040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.